Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.

Nathalie Letarte,Layal El Raichani,Chantal Guévremont,Nathalie Marcotte,Ghislain Bérard,Marie-Claude Michel,Élaine Pelletier,Paul Farand,Louise Deschênes,Daniel Froment,Philippe Ovetchkine,Marie-Andrée Fournier,Normand Blais,Raghu Rajan,Rahima Jamal

Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.

2019

Nathalie Letarte
Layal El Raichani
Chantal Guévremont
Nathalie Marcotte
Ghislain Bérard
Marie-Claude Michel
Élaine Pelletier
Paul Farand
Louise Deschênes
Daniel Froment
Philippe Ovetchkine
Marie-Andrée Fournier
Normand Blais
Raghu Rajan
Rahima Jamal

e14125Background: Nivolumab and pembrolizumab, two anti-PD1 agents, were approved and funded in Quebec since 2016 for non small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma. Th...

Keywords:

Physical therapy
Nivolumab
Pembrolizumab
Family medicine
Medicine
Lung cancer
university teaching
Pathology
Oncology
Internal medicine
Melanoma
non small cell
Renal cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations